Royal Queen Seeds Presented New F1 Hybrids to Industry
The owner and two biologists at Royal Queen Seeds recently presented their F1 hybrid process and strains in Barcelona, Spain.
On March 10, 2023 Royal Queen Seeds (RQS), a seed bank in Europe, presented their newly released F1 hybrid varieties to growers, journalists, and others in the cannabis industry at the Hotel Novotel in Cornellà near Spannabis—the largest annual cannabis fair in the world (1).
One of the owners, Shai Ramsahai, introduced the company and its journey, then biologist Maikel de Bresser explained the process involved in creating F1 hybrids—from selecting desirable parent material to developing inbred lines (IBLs). Plant geneticist Andreu Francés explained the research involved in the project and the results the team have achieved, highlighting the new eight F1s he helped develop, including: Medusa F1, Orion F1, and Milky Way F1, which are all autoflowering varieties.
RQS recently expanded into the US and Thailand and now supply cannabis genetics worldwide.
Reference
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
